The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics; Biogen; Gilead Sciences
Travel, Accommodations, Expenses - Allogene Therapeutics
 
Employment - Allogene Therapeutics
First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.
 
Sattva Swarup Neelapu
Honoraria - Aptitude Health; Bio Ascend; Medscape; MJH Life Sciences
Consulting or Advisory Role - Alimera Sciences; Celgene; Cell Medica; Gilead Sciences; Incyte; Kite, a Gilead company; Legend Biotech; Merck Sharp & Dohme; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
Research Funding - Acerta Pharma; Alimera Sciences; Bristol-Myers Squibb; Cellectis; Gilead Sciences; Karus Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; poseida therapeutics; Precision Biosciences; Unum Therapeutics
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy
Travel, Accommodations, Expenses - Alimera Sciences; Celgene; Chugai Pharma; Kite/Gilead; Legend Biotech; Medscape; Merck; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
 
Javier Munoz
Honoraria - Kyowa Hakko Kirin; Seagen
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Fosun Kite; Genentech; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Frederick Lundry Locke
Stock and Other Ownership Interests - Cellular Biomedicine Group
Consulting or Advisory Role - Alimera Sciences; Calibr; Celgene; Cellular Biomedicine Group; EcoR1 Capital; GammaDelta Therapeutics; Gerson Lehrman Group; Novartis; WUGEN, Inc.
Research Funding - Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
David Bernard Miklos
Consulting or Advisory Role - Adaptive Biotechnologies; Alimera Sciences; Janssen; Juno/Celgene; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics; Precision Biosciences
Research Funding - Adaptive Biotechnologies; Alimera Sciences; Kite, a Gilead company; Novartis; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Juno Therapeutics; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics/Janssen
 
Robert Brown
No Relationships to Disclose
 
Jennifer T. McDevitt
Employment - Allogene Therapeutics
 
Armen Mardiros
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Gilead Sciences
Patents, Royalties, Other Intellectual Property - MustangBio
 
Eren Demirhan
No Relationships to Disclose
 
Cyril Konto
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics; Bristol-Myers Squibb; Forty Seven; MorphoSys; Pfizer
Patents, Royalties, Other Intellectual Property - Allogene Therapeutics; Bristol-Myers Squibb; Pfizer
 
Michael Timothy Tees
Speakers' Bureau - Celgene; Pharmacyclics